Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized chamber, typically at 1.5–3.0 atmospheres absolute (ATA). This dramatically increases oxygen dissolution in plasma and delivery to tissues, even in areas with poor blood flow. The therapy triggers multiple physiological responses: it corrects tissue hypoxia, modulates inflammation, promotes angiogenesis via factors like vascular endothelial growth factor (VEGF), enhances neuroplasticity, and supports cellular repair mechanisms. While HBOT has long-established uses for conditions like decompression sickness and carbon monoxide poisoning, high-quality randomized controlled trials (RCTs) and systematic reviews published in peer-reviewed journals have increasingly examined its role in wound healing, chronic pain, neurological recovery, and cognitive health.
This article reviews evidence from meta-analyses and RCTs in scientific journals, focusing on clinically meaningful outcomes. It also incorporates detailed biomarker data from Bryan Johnson’s rigorous self-experimentation with HBOT as part of his Blueprint longevity protocol, an N=1 case study with extensive pre- and post-intervention testing that provides real-world insights into potential anti-aging applications.
Established Benefits: Wound Healing and Diabetic Foot Ulcers
One of the strongest bodies of evidence supports HBOT as an adjunctive therapy for diabetic foot ulcers (DFUs), a major complication of diabetes linked to poor oxygenation and impaired healing. A 2021 systematic review and meta-analysis in Scientific Reports pooled data from 14 controlled clinical trials (12 RCTs and 2 controlled clinical trials) involving 768 participants. HBOT significantly improved complete ulcer healing compared to standard wound care alone (odds ratio [OR] = 0.29; 95% confidence interval [CI] 0.14–0.61; I² = 62%). It also reduced the risk of major amputations (risk ratio [RR] = 0.60; 95% CI 0.39–0.92; I² = 24%). No significant differences emerged for minor amputations, overall ulcer area reduction, or mortality, though adverse events were more common in the HBOT group (RR = 1.68; 95% CI 1.07–2.65). The authors concluded that HBOT is an effective adjunct for promoting healing and limb salvage in DFUs, though larger trials are needed to refine protocols.
These findings align with earlier evidence syntheses, including moderate-quality data from systematic reviews showing HBOT’s ability to enhance tissue oxygenation, reduce edema, and combat infection in hypoxic wounds.
Neurological and Pain-Related Benefits: Fibromyalgia and Traumatic Brain Injury
HBOT shows promise for conditions involving chronic inflammation, hypoxia, and impaired neuroplasticity. A 2023 systematic review and meta-analysis in BMJ Open examined HBOT for fibromyalgia, a disorder characterized by widespread pain, fatigue, and sleep disturbances. Nine studies (3 RCTs and 6 non-randomized controlled trials) with 288 patients were included. Meta-analysis of the RCTs demonstrated a large pain reduction (standardized mean difference [SMD] = −1.56; 95% CI −2.18 to −0.93; p < 0.001; I² = 51%). Most studies also reported improvements in tender points, fatigue, multidimensional function, patient global assessment, and sleep disturbance. Adverse events occurred in 23.8% of patients (primarily mild barotrauma), with 6.5% withdrawing. No serious complications were noted. Evidence quality for pain relief was rated moderate, supporting HBOT as a potential option for symptom relief in fibromyalgia, particularly at pressures below 2.0 ATA to minimize side effects.
For traumatic brain injury (TBI), a 2025 systematic review and meta-analysis (published in Annals of Medicine and Surgery) analyzed four studies involving 250 patients. HBOT produced significant neurocognitive gains across domains: memory (mean difference [MD] 10.13; p < 0.00001), attention (MD 7.99; p < 0.00001), general cognition (MD 7.47; p = 0.003), executive function (MD 7.16; p = 0.002), information processing speed (MD 7.48; p = 0.01), and motor skills (MD 5.19; p < 0.00001). The authors highlighted HBOT’s potential to mitigate TBI-related deficits, with low risk of bias in the RCTs.
To learn more, see Tips to Reduce Recovery Time After Traumatic Brain Injury
A 2020 RCT in Aging (Impact Journals) tested HBOT specifically for cognitive enhancement in healthy older adults. In this double-blind trial, 63 participants (mean age ~70) received 60 sessions of 100% oxygen at 2 ATA (90 minutes each, with air breaks) or no intervention. The HBOT group showed significant gains in global cognitive function (p = 0.0017. Net effect size 0.849), with the largest improvements in information processing speed (effect size 0.788) and attention (effect size 0.745). Perfusion MRI revealed increased cerebral blood flow in frontal and parietal regions critical for executive function, correlating directly with cognitive scores. The authors attributed benefits to angiogenesis and neuroplasticity induced by intermittent hyperoxia.
Emerging Applications: PTSD, Stroke, and Quality of Life
High-quality reviews have explored HBOT for post-traumatic stress disorder (PTSD). A 2024 systematic review and dosage analysis in Frontiers in Neurology found statistically significant and clinically meaningful symptom improvements across multiple RCTs using 40–60 sessions at 1.3–2.0 ATA. Benefits scaled with cumulative oxygen dose, accompanied by brain imaging changes in some studies. Side effects were mostly transient.
For acute ischemic stroke, a 2024 meta-analysis in BMC Neurology (8 studies, 493 patients) found no broad superiority in NIHSS scores or inflammatory markers, but noted modest improvement in modified Rankin Scale scores and fewer adverse events at treatment end. The authors called for further research on optimal timing and patient subgroups.
Broader quality-of-life (QOL) benefits appear across conditions. A review in the Archives of Medical and Health Sciences Research reported significant QOL gains in patients with diabetic foot ulcers, post-concussion syndrome, post-radiotherapy complications, stroke, and fibromyalgia, with HBOT deemed safe overall.
Bryan Johnson’s HBOT Experiments: A Detailed N=1 Analysis
Tech entrepreneur and longevity advocate Bryan Johnson integrated HBOT into his Blueprint protocol, conducting a controlled self-experiment with comprehensive biomarker tracking. His protocol mirrored protocols in the cognitive-aging RCT: 60 sessions over ~12 weeks (5 per week), 90 minutes each at 2 ATA, breathing 100% oxygen via mask (with 20-minute oxygen periods alternated with 5-minute air breaks in a hard-shell chamber). Sessions emphasized safety (no electronics inside due to fire risk).
Post-intervention results (reported in early 2025) were striking and multi-systemic. Systemic inflammation dropped to undetectable levels, with a high-sensitivity C-reactive protein (hs-CRP) epigenetic proxy shifting from the top 5% to the bottom 1% for young adults. VEGF surged 300%, correlating with improved muscle oxygenation (equivalent to doubled power output capacity). Telomerase activity reached levels typical of a 12-year-old, with telomere lengthening and senescent cell reduction aligning with prior clinical trial data on immune-cell rejuvenation. Gut microbiome metrics improved dramatically: short-chain fatty acids rose 250%, n-butyrate 290%, and metabolic imbalances fully resolved despite no dietary changes. A dementia biomarker (pTau217) fell 28.6% (from 0.14 to 0.1 pg/mL), placing it in a range associated with lower Alzheimer’s risk and better memory/processing speed. Skin health advanced noticeably. Facial biological age dropped from 39 to 38 years, with UV damage scores improving from the 55th to 68th percentile, possibly due to reduced advanced glycation end-products.
Johnson described HBOT as “one of the highest value health therapies” he has tested, uniquely moving multiple elite-level biomarkers further after years of optimization. He contextualized results against published trials showing HBOT’s effects on telomeres, VO2 max, and amyloid reduction, while noting accessible alternatives (sauna, exercise, Mediterranean diet) share overlapping mechanisms.
Short HBOT summary reel from Bryan Johnson’s Instagram account
Longer video (13:20 min) on HBOT protocol and results from Bryan Johnson’s YouTube channel
Safety Profile and Considerations
HBOT is generally well-tolerated, but not risk-free. A 2023 systematic review and meta-analysis in Frontiers in Medicine (24 RCTs, 1,497 participants) found higher adverse event rates with HBOT (30.11% vs. 10.43% in controls; RR = 2.89). The most common issue was ear discomfort/barotrauma. Risks rose with >10 sessions or pressures >2.0 ATA, but remained manageable and reversible at standard protocols. No serious long-term complications were widely reported.
Conclusion
High-quality evidence from journals demonstrates HBOT’s efficacy for diabetic wound healing, fibromyalgia symptom relief, TBI neurocognitive recovery, and age-related cognitive enhancement, primarily through enhanced oxygenation, angiogenesis, and anti-inflammatory pathways.
Bryan Johnson’s meticulously tracked experiment extends these findings into longevity territory, revealing broad biomarker improvements in inflammation, vascular health, telomeres, microbiome, brain, and skin. This positions HBOT as a high-impact intervention for optimized individuals.
While promising, many applications remain adjunctive or investigational, such as optimal dosing, patient selection, and long-term outcomes require further large-scale RCTs. For those considering HBOT, consultation with a qualified medical provider is essential to weigh benefits against mild, reversible risks. As research evolves, HBOT may emerge as a versatile tool not only for treating disease, but for supporting healthy aging.
📚 Sources and References
- A General Overview on the Hyperbaric Oxygen Therapy: Applications, Mechanisms and Translational Opportunities (2021)
- Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials (2021), published in Nature
- Efficacy and safety of hyperbaric oxygen therapy for fibromyalgia: a systematic review and meta-analysis (2023), published in BMJ Open
- Hyperbaric oxygen therapy (HBOT) for neurocognitive deficits following traumatic brain injury: a systematic review and meta-analysis (2025), published in Annals of Medicine & Surgery
- Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial (2020), published in Aging
- Systematic review and dosage analysis: hyperbaric oxygen therapy efficacy in the treatment of posttraumatic stress disorder (2024), published in Frontiers Neurology
- Efficacy and safety of hyperbaric oxygen therapy in acute ischaemic stroke: a systematic review and meta-analysis (2024), published in BMC Journals
- Hyperbaric Oxygen Therapy and Quality of Life: A Systematic Review (2017), published in Annals of Military and Health Sciences Research
- Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis (2023), published in Frontiers in Medicine
- Bryan Johnson’s HBOT protocol
Leave a Reply